Immunotherapeutic efficiency of a tetravalent Aβ1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer’s disease

References

• Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 2011; 108:5819 - 24; http://dx.doi.org/10.1073/pnas.1017033108; PMID: 21421841
   PubMed Web of Science ®Google Scholar
• Sakono M, Zako T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J 2010; 277:1348 - 58; http://dx.doi.org/10.1111/j.1742-4658.2010.07568.x; PMID: 20148964
   PubMed Web of Science ®Google Scholar
• Qu BX, Xiang Q, Li L, Johnston SA, Hynan LS, Rosenberg RN. Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci 2007; 260:204 - 13; http://dx.doi.org/10.1016/j.jns.2007.05.012; PMID: 17574274
   PubMed Web of Science ®Google Scholar
• Weksler ME, Gouras G, Relkin NR, Szabo P. The immune system, amyloid-beta peptide, and Alzheimer’s disease. Immunol Rev 2005; 205:244 - 56; http://dx.doi.org/10.1111/j.0105-2896.2005.00264.x; PMID: 15882358
   PubMed Web of Science ®Google Scholar
• Wisniewski T, Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol 2005; 15:72 - 7; http://dx.doi.org/10.1111/j.1750-3639.2005.tb00102.x; PMID: 15779239
   PubMed Web of Science ®Google Scholar
• Citron M. Strategies for disease modification in Alzheimer’s disease. Nat Rev Neurosci 2004; 5:677 - 85; http://dx.doi.org/10.1038/nrn1495; PMID: 15322526
   PubMed Web of Science ®Google Scholar
• Singh H, Raghava GP. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 2003; 19:1009 - 14; http://dx.doi.org/10.1093/bioinformatics/btg108; PMID: 12761064
   PubMed Web of Science ®Google Scholar
• Walsh DT, Bresciani L, Saunders D, Manca MF, Jen A, Gentleman SM, et al. Amyloid beta peptide causes chronic glial cell activation and neuro-degeneration after intravitreal injection. Neuropathol Appl Neurobiol 2005; 31:491 - 502; http://dx.doi.org/10.1111/j.1365-2990.2005.00666.x; PMID: 16150120
   PubMed Web of Science ®Google Scholar
• Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, et al. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011; 31:9323 - 31; http://dx.doi.org/10.1523/JNEUROSCI.0293-11.2011; PMID: 21697382
   PubMed Web of Science ®Google Scholar
• Maier M, Seabrook TJ, Lemere CA. Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). Vaccine 2005; 23:5149 - 59; http://dx.doi.org/10.1016/j.vaccine.2005.06.018; PMID: 16054274
   PubMed Web of Science ®Google Scholar
• Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003; 15:505 - 14; http://dx.doi.org/10.1093/intimm/dxg049; PMID: 12663680
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 2012; 30:4341 - 8; http://dx.doi.org/10.1016/j.vaccine.2011.09.061; PMID: 22682289
   PubMed Web of Science ®Google Scholar
• Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003; 62:1087 - 95; PMID: 14656067
   PubMed Web of Science ®Google Scholar
• Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, et al. Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies. Immunotherapy 2012; 4:213 - 38; http://dx.doi.org/10.2217/imt.11.170; PMID: 22339463
   PubMed Web of Science ®Google Scholar
• Frisardi V, Solfrizzi V, Imbimbo PB, Capurso C, D’Introno A, Colacicco AM, et al. Towards disease-modifying treatment of Alzheimer’s disease: drugs targeting beta-amyloid. Curr Alzheimer Res 2010; 7:40 - 55; http://dx.doi.org/10.2174/156720510790274400; PMID: 19939231
   PubMed Web of Science ®Google Scholar
• Chackerian B, Rangel M, Hunter Z, Peabody DS. Virus and virus-like particle-based immunogens for Alzheimer’s disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine 2006; 24:6321 - 31; http://dx.doi.org/10.1016/j.vaccine.2006.05.059; PMID: 16806604
   PubMed Web of Science ®Google Scholar
• Wisniewski T. Active immunotherapy for Alzheimer’s disease. Lancet Neurol 2012; 11:571 - 2; http://dx.doi.org/10.1016/S1474-4422(12)70136-9; PMID: 22677257
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. J Immunol 2005; 175:5 - 14; PMID: 15972624
   PubMed Web of Science ®Google Scholar
• Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S, et al. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci 2009; 29:11393 - 8; http://dx.doi.org/10.1523/JNEUROSCI.2021-09.2009; PMID: 19741145
   PubMed Web of Science ®Google Scholar
• Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012; 11:597 - 604; http://dx.doi.org/10.1016/S1474-4422(12)70140-0; PMID: 22677258
   PubMed Web of Science ®Google Scholar
• Leverone JF, Spooner ET, Lehman HK, Clements JD, Lemere CA. Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for “boosting”. Vaccine 2003; 21:2197 - 206; http://dx.doi.org/10.1016/S0264-410X(02)00754-5; PMID: 12706711
   PubMed Web of Science ®Google Scholar
• Guruprasad K, Rajkumar S. Beta-and gamma-turns in proteins revisited: a new set of amino acid turn-type dependent positional preferences and potentials. J Biosci 2000; 25:143 - 56; PMID: 10878855
   PubMed Web of Science ®Google Scholar
• Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006; 26:10129 - 40; http://dx.doi.org/10.1523/JNEUROSCI.1202-06.2006; PMID: 17021169
   PubMed Web of Science ®Google Scholar
• Biancalana M, Koide S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta 2010; 1804:1405 - 12; http://dx.doi.org/10.1016/j.bbapap.2010.04.001; PMID: 20399286
   PubMed Web of Science ®Google Scholar
• Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer’s disease: uncovering the secrets of secretases. Curr Opin Neurobiol 2001; 11:585 - 90; http://dx.doi.org/10.1016/S0959-4388(00)00253-1; PMID: 11595492
   PubMed Web of Science ®Google Scholar
• Smith WB, Guida L, Sun Q, Korpelainen EI, van den Heuvel C, Gillis D, et al. Neutrophils activated by granulocyte-macrophage colony-stimulating factor express receptors for interleukin-3 which mediate class II expression. Blood 1995; 86:3938 - 44; PMID: 7579364
   PubMed Web of Science ®Google Scholar
• Lee HG, Zhu X, Nunomura A, Perry G, Smith MA. Amyloid beta: the alternate hypothesis. Curr Alzheimer Res 2006; 3:75 - 80; http://dx.doi.org/10.2174/156720506775697124; PMID: 16472207
   PubMedGoogle Scholar
• Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, et al. Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 2001; 30:447 - 50; http://dx.doi.org/10.1016/S0891-5849(00)00494-9; PMID: 11182300
   PubMed Web of Science ®Google Scholar
• Lynch MA, Mills KH. Immunology meets neuroscience--opportunities for immune intervention in neurodegenerative diseases. Brain Behav Immun 2012; 26:1 - 10; http://dx.doi.org/10.1016/j.bbi.2011.05.013; PMID: 21664452
   PubMed Web of Science ®Google Scholar
• Gosselin EJ, Wardwell K, Rigby WF, Guyre PM. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-gamma, and IL-3. J Immunol 1993; 151:1482 - 90; PMID: 8335942
   PubMed Web of Science ®Google Scholar
• Ferrer I, Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease. Brain Pathol 2004; 14:11 - 20; http://dx.doi.org/10.1111/j.1750-3639.2004.tb00493.x; PMID: 14997933
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lee DH. Sink hypothesis and therapeutic strategies for attenuating Abeta levels. Neuroscientist 2011; 17:163 - 73; http://dx.doi.org/10.1177/1073858410381532; PMID: 21330304
   PubMed Web of Science ®Google Scholar
• Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C. Oxidation of Abeta and plaque biogenesis in Alzheimer’s disease and Down syndrome. Neurobiol Dis 2001; 8:792 - 806; http://dx.doi.org/10.1006/nbdi.2001.0431; PMID: 11592849
   PubMed Web of Science ®Google Scholar
• Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer’s disease mouse models. J Exp Med 2008; 205:2781 - 9; http://dx.doi.org/10.1084/jem.20081588; PMID: 18955571
   PubMed Web of Science ®Google Scholar